The Evolving Landscape of Risk Management in 2026
Every medicine carries inherent risks — a predictable outcome of pharmacological action and patient variability. While most are known and routinely managed, some products present unique safety challenges because of their pharmacokinetic or pharmacodynamic properties. These are captured and actively managed through a Risk Management Plan (RMP) — the foundation of modern pharmacovigilance strategy — outlining known, potential, and emerging safety concerns.
When a medicine’s profile identifies specific safety risks, additional Risk Minimisation Measures (RMMs) are required. These include materials and systems designed to support healthcare professionals (HCPs), patients, and carers in using medicines safely. Importantly, these tools are educational, not promotional — ensuring scientific integrity and regulatory compliance.
From Leaflets to Digital Risk Platforms
The way we communicate and manage risk has evolved rapidly. As patients have become more informed and digital health tools have matured, electronic RMMs are now standard practice. From interactive e-learning modules and online prescriber checklists to patient engagement portals, the industry has embraced platforms that ensure reach, speed, and traceability.
At the same time, accessibility remains paramount. While digital-first is increasingly preferred by regulators such as the MHRA, print and hybrid solutions still play a vital role for certain patient groups — particularly older populations or those with limited technical access. The key is flexibility: tailoring communication to the audience, not the other way around.
The Rising Complexity of RMMs
Today’s RMMs can range from simple patient reminder cards to complex Pregnancy Prevention Programmes (PPPs) — each demanding different levels of coordination and oversight. Factors influencing RMM complexity include:
Number and format of materials (print, digital, in-pack)
Distribution channels (mailing, online platforms, pharmacy networks)
Target audiences (patients, carers, HCPs — general or specialist)
Monitoring systems (registries, follow-up questionnaires)
Regulatory reviews and inspections (pre- and post-launch)
Any combination of the above
At Pharmaguard Consultancy, we have extensive experience designing and managing RMMs that balance compliance, efficiency, and patient-centricity. Our team helps Marketing Authorisation Holders (MAHs) navigate every stage — from concept to MHRA approval — ensuring that risk minimisation tools are both effective and measurable.
Lessons from the Field
Our consultants have worked across a wide portfolio of generic and branded medicines, supporting clients through both routine and complex RMMs. One of our most challenging yet rewarding projects involved developing and maintaining the Pregnancy Prevention Programme for generic thalidomide, lenalidomide, and pomalidomide — an initiative that required close collaboration with the MHRA and multiple stakeholders across the supply chain.
As digital transformation accelerates and regulatory expectations evolve, effective risk management is more critical than ever. At Pharmaguard, we combine regulatory expertise with practical operational insight to help our clients protect patients, maintain compliance, and deliver confidence in every product journey.